argenx (NASDAQ:ARGX – Free Report) had its target price hoisted by Stifel Nicolaus from $557.00 to $560.00 in a research note released on Monday, Benzinga reports. The brokerage currently has a buy rating on the stock. ARGX has been the subject of a number of other reports. HC Wainwright dropped their target price on shares […]
Argenx stock lost a third of its value as the Amsterdam biotech said a late-stage trial did not meet primary or secondary endpoints. The Phase 3 study was of.
argenx (NASDAQ:ARGX – Free Report) had its price target upped by TD Cowen from $612.00 to $641.00 in a research note issued to investors on Tuesday, Benzinga reports. TD Cowen currently has an outperform rating on the stock. ARGX has been the subject of several other reports. Raymond James lowered their target price on shares […]
argenx (NASDAQ:ARGX – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings. Volatility and Risk argenx has a beta of 0.79, […]
Genus Capital Management Inc. acquired a new position in argenx SE (NASDAQ:ARGX – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,580 shares of the company’s stock, valued at approximately $616,000. Several other large investors have also recently bought and sold […]